PB-119
GLP-1 · s.c. weekly · PegBio
Summary
- Also known as
- PegBio (PEGylated exenatide)
- Mechanism
- GLP-1
- Route
- s.c. weekly
- Company
- PegBio
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China for T2D (November 2025) verify
- Next milestone
- Obesity development
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 1 phase 2 / signal | Phase 2 only | |
| T2D | 4 approved / in label | NMPA (China), November 2025 | PegBio HKEX announcement (Nov 2025) |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197) | 150 μg QW | t2d china | 24 | 310 | — | — | −1.2 vs −0.7 | — | 7.4 vs 7.7 | 4.2 vs 0.3 | 4.8 vs 0.3 | 2.9 vs 3.9 | — | press release |
| Phase 3 monotherapy (NCT04504370) | 150 μg QW | t2d china | 24 | 137 | — | — | −1.4 vs −0.6 | 2.2 | 4.4 vs 7.4 | 8.0 vs 0.7 | 5.8 vs 0.0 | 6.6 vs 1.5 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 150 μg QW: Reported 1.9 % for Table 3 row is "TRAE leading to early withdrawal" (treatment-related AEs) 6/310 vs 1/310 (0.3%); text calls the same numbers "due to TEAEs" — inconsistent (not shown on the axis).
Verbatim quotes from the source (11)
- 150 μg QW · hba1c · publication
the least squares mean (LSM) change from baseline in HbA1c was −1.36% (95% CI 1.52 to −1.20)
- 150 μg QW · nausea · Table 4 (safety set; double-blind 24-week period; Visepegena
Nausea 11 (8.0) 32 1 (0.7)
- 150 μg QW · vomiting · Table 4 (safety set; double-blind 24-week period; Visepegena
Vomiting 8 (5.8) 14 0 (0.0)
- 150 μg QW · ae_dc · publication
The common cause of treatment discontinuation was AE in three (2.2%) participants of the visepegenatide group
- 150 μg QW · disc_any · publication
Six (4.4%) participants received visepegenatide and 10 (7.4%) participants received placebo discontinued the treatment in the double-blinded treatment period.
- 150 μg QW · sae · Table 4 (safety set; double-blind 24-week period; Visepegena
Serious Adverse Events (SAEs) 9 (6.6) 10 2 (1.5)
- 150 μg QW · hba1c · publication
was −1.25% (95% confidence interval (CI), −1.35 to −1.16) in the visepegenatide group and −0.68% (95% CI, −0.78 to −0.59) in the placebo group.
- 150 μg QW · disc_any · Results, first paragraph
During the 24-week double-blind period, 287 (92.6%) participants in the visepegenatide group and 286 (92.2%) participants in the placebo group completed the treatment and entered the extension phase.
- 150 μg QW · nausea · Table 3, double-blind columns (Visepegenatide N=310, Placebo
Nausea 13 (4.2) 31 1 (0.3)
- 150 μg QW · sae · Table 3, double-blind columns
Serious adverse events (SAEs) 9 (2.9) 10 12 (3.9)
- 150 μg QW · vomiting · Table 3, double-blind columns
Vomiting 15 (4.8) 30 1 (0.3)
Registered trials (2)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT04504396 Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy | T2D | Phase 3 | completed | 2020-06 → 2022-09 | 620 | Completed; results not in the atlas yet | NCT04504396 |
| PB119 Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects | T2D | Phase 3 | completed | 2020-04 → 2022-03 | 273 | Completed; results not in the atlas yet | NCT04504370 |
Primary sources
- PegBio. Efficacy and safety of visepegenatide (PB-119) as monotherapy in T2DM: phase 3 RCT. Lancet Reg Health West Pac 2024;47:101101 [publication]. 2024-06. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11214404/
- PegBio. Efficacy and safety of visepegenatide (PB-119) as add-on to metformin in T2DM: phase 3 RCT. Lancet Reg Health West Pac 2024;51:101197 [publication]. 2024-10. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11488426/
How to cite this page
Cite the primary publication for any single result; every value above links to it.